US20130273034A1 - Novel compounds and compositions for the inhibition of nampt - Google Patents

Novel compounds and compositions for the inhibition of nampt Download PDF

Info

Publication number
US20130273034A1
US20130273034A1 US13/820,496 US201113820496A US2013273034A1 US 20130273034 A1 US20130273034 A1 US 20130273034A1 US 201113820496 A US201113820496 A US 201113820496A US 2013273034 A1 US2013273034 A1 US 2013273034A1
Authority
US
United States
Prior art keywords
phenyl
pyridin
ylmethyl
urea
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/820,496
Other languages
English (en)
Inventor
Kenneth W. Bair
Timm R. Baumeister
Alexandre J. Buckmelter
Karl H. Clodfelter
Bingsong Han
Jian Lin
Dominic J. Reynolds
Chase C. Smith
Zhongguo Wang
Xiaozhang Zheng
Po-Wai Yuen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Forma Therapeutics Inc
Valo Early Discovery Inc
Pharmaron Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/820,496 priority Critical patent/US20130273034A1/en
Application filed by Individual filed Critical Individual
Assigned to GENENTECH, INC reassignment GENENTECH, INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YUEN, PO-WAI
Assigned to FORMA THERAPEUTICS, INC. reassignment FORMA THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SMITH, CHASE C., BAIR, KENNETH W., BAUMEISTER, TIMM, BUCKMELTER, ALEXANDRE J., CLODFELTER, KARL H., WANG, ZHONGGUO, ZHENG, XIAOZHANG, LIN, JIAN, HAN, BINGSONG, REYNOLDS, DOMINIC J.
Assigned to GENENTECH, INC. reassignment GENENTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHARMARON, INC.
Assigned to FORMA THERAPEUTICS INC. reassignment FORMA THERAPEUTICS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAUMEISTER, TIMM R., REYNOLDS, DOMINIC J., CLODFELTER, KARL H., SMITH, CHASE C., BAIR, KENNETH W., BUCKMELTER, ALEXANRE J., HAN, BINGSONG, LIN, JIAN, WANG, ZHONGGUO, ZHENG, XIAOZHANG
Assigned to PHARMARON BEIJING, CO., LTD reassignment PHARMARON BEIJING, CO., LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YUEN, PO-WAI
Assigned to PHARMARON, INC. reassignment PHARMARON, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHARMARON BEIJING, CO., LTD
Publication of US20130273034A1 publication Critical patent/US20130273034A1/en
Assigned to FORMA TM, LLC. reassignment FORMA TM, LLC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORMA THERAPEUTICS, INC.
Assigned to FORMA THERAPEUTICS, INC. reassignment FORMA THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORMA TM, LLC
Assigned to INTEGRAL EARLY DISCOVERY, INC. reassignment INTEGRAL EARLY DISCOVERY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORMA THERAPEUTICS, INC.
Assigned to VALO EARLY DISCOVERY, INC. reassignment VALO EARLY DISCOVERY, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: INTEGRAL EARLY DISCOVERY, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Definitions

  • the present invention relates to compounds and composition for inhibition of Nicotinamide phosphoribosyltransferase (“NAMPT”), their synthesis, applications and antidote.
  • NAMPT Nicotinamide phosphoribosyltransferase
  • Nicotinamide adenine dinucleotide plays fundamental roles in both cellular energy metabolism and cellular signaling.
  • energy metabolism the chemistry of the pyridine ring allows NAD to readily accept and donate electrons in hydride transfer reactions catalyzed by numerous dehydrogenases.
  • FK866 International Non-proprietary Name
  • APP866 APP866
  • FK866 FK175, WK22.175
  • FK866 International Non-proprietary Name
  • FK866 may be used for treatment of diseases implicating deregulated apoptosis such as cancer. It has been demonstrated in the prior art that FK866 interferes with nicotinamide adenyl dinucleotide (also known and hereinafter referred to as NAD) biosynthesis and induces apoptotic cell death without any DNA damaging effects.
  • NAD nicotinamide adenyl dinucleotide
  • FK866 (E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl)acrylamide induces apoptosis in HepG2 cells without having primary effects on cellular energy metabolism.
  • Hasmann M Schemainda I.
  • FK866 a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis. Cancer Res 2003; 63:7436-7442.
  • FK866 In a mouse mammary carcinoma model, FK866 also induces a delay in tumor growth and an enhancement in tumor radiosensitivity accompanied with dose-dependent decreases in NAD levels, pH, and energy status. A chemosensitizing effect of FK866 has also been observed on anti-neoplastic 1-methyl-3-nitro-1-nitrosoguanidinium (MNNG)-induced cell death in THP-1 and K562 leukemia cell lines (Pogrebniak A, et al. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 2006; 11:313-321. [PubMed: 17052966]).
  • MNNG anti-neoplastic 1-methyl-3-nitro-1-nitrosoguanidinium
  • GMX1777 The efficacy of GMX1777 was evaluated in xenograft models and the pharmacokinetic profile of GMX1778 and its effect on nicotinamide adenine dinucleotide cellular levels was measured by liquid chromatography/mass spectrometry. (Beauparlant P., et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs. 2009 June; 20(5):346-54).
  • GMX1777 is a water-soluble intravenously administered prodrug of GMX1778 that Gemin X in-licensed from LEO Pharma (LEO numbers: EB 1627 and CHS828, respectively). These compounds and other substituted cyanoguanidines have the structures of Table 1. None of the compounds of the present invention are cyanoguanidines.
  • CHS-828 has been identified as a NAMPT inhibitor (Olesen U H, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008; 367:799-804. [PubMed: 18201551]). CHS-828 has been shown that this compound potently inhibits cell growth in a broad range of tumor cell lines, although the detailed mechanism for this inhibitory effect of CHS-828 remains undetermined (Ravaud A, et al. Phase I study and guanidine kinetics of CHS-828, a guanidine-containing compound, administered orally as a single dose every 3 weeks in solid tumors: an ECSG/EORTC study. Eur J Cancer 2005; 41:702-707. [PubMed: 15763645]). Both FK866 and CHS-828 are currently in clinical trials for cancer treatments.
  • NAMPT may also have effects on endothelium (EC) in relation to high glucose levels, oxidative stress and on aging. It is also believed that NAMPT may enable proliferating human EC to resist the oxidative stress of aging and of high glucose, and to productively use excess glucose to support replicative longevity and angiogenic activity.
  • EC endothelium
  • One aspect of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals having a compound of the Formula I:
  • Another aspect of this invention is the provision of compounds of Formula I where X, L, Q, Ar 1 and A are as defined in Formula I and R 1 is selected from H, a straight or branched C 1 to C 7 alkyl, straight or branched C 1 to C 7 alkoxy, straight or branched C 1 to C 4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, arylalkyl-, heteroarylalkyl-, heterocycloalkylalkyl-, cycloalkylalkyl-, hydroxyalkyl-, alkoxyalkyl-, spiroheterocycloalkyl and heterospiroheterocycloalkyl, wherein the heteroatoms of said heteroaryl and heterocycloalkyl in the moieties above are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein R 1 can be either unsub
  • R 2 is selected from H, a straight or branched C 1 to C 7 alkyl, straight or branched C 1 to C 7 alkoxy, straight or branched C 1 to C 4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, arylalkyl-, heteroarylalkyl-, heterocycloalkylalkyl-, cycloalkylalkyl-, hydroxyalkyl-, alkoxyalkyl-, spiroheterocycloalkyl and heterospiroheterocycloalkyl, wherein the heteroatoms of said heteroaryl and heterocycloalkyl in the moieties above are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein R 2 can be either unsubstituted or optionally independently (i) either substituted with one or more substituents which can be the same or different and are independently selected
  • the compound of Formula I is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridine-4-ylmethyl)thiourea or 3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • Another aspect of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals having a compound of the Formula II:
  • Another aspect of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals derived from compounds of Formula I and Formula II and having the formula of Formula III:
  • Ar 1 is 5 to 12 membered heteroaryl comprising 1, 2, 3 or 4 heteroatom(s) independently selected from N, S or O, wherein said heteroaryl is unsubstituted or substituted by one or more R a selected from the group consisting of —NH 2 , oxo, halo, haloalkyl, —NH(CO)O-alkyl, —C(O)NH 2 and 3,4-dihydroxy-5-methyltetrahydrofurane; and wherein said heteroaryl can comprise one or more N-oxide(s) formed with a N atom member of said heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
  • Ar 2 is aryl or 5 or 6 membered heteroaryl comprising 1, 2, 3 or 4 heteroatom(s) independently selected from N, S or O;
  • R is H, a straight or branched C 1 -C 6 alkyl, or arylalkyl
  • R 1 is —NR 3 R 4 wherein R 3 is H, alkyl or —S(O) 2 alkyl and R 4 is alkyl, hydroxyalkyl, —S(O) 2 alkyl, —(CH 2 ) q cycloalkyl, —(CH 2 ) q heterocycloalkyl, aryl, arylalkyl-, —(CH 2 ) q heteroaryl;
  • R 2 is O or absent
  • R b and R c are independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxy, aryl, alkoxyalkyl, —S(O) 2 alkyl and cycloalkyl or R b and R c can form a 5 or 6 membered heterocycloalkyl group together with the nitrogen atom to which they are attached, wherein said heterocycloalkyl group may contain one or more additional heteroatom(s) selected from N, S or O;
  • n 0, or 1;
  • q 0, 1 or 2;
  • the compound of Formula III is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridine-4-ylmethyl)thiourea or 3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • Another embodiment of the invention is the provision of a compound of Formula III where Ar 1 is pyridine, n is 1, Ar 2 is phenyl and the Formula becomes Formula IIIA:
  • Another aspect of this invention is the provision of methods of treating a disease via the inhibition of NAMPT in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Still another aspect of this invention is to provide a method for treating, preventing, inhibiting or eliminating a disease or condition in a patient by inhibiting NAMPT in said patitent by administering a therapeutically affective amount of at least one compound of this disclosure, wherein said disease or condition is selected from the group consisting of cancer, ovarian cancer, breast casncer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteaoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple
  • Another preferred embodiment is a pharmaceutical formulation comprising a pharmaceutically acceptable compound of the present invention, which provides, upon administration to a human, a decrease in tumor burden and/or metastases.
  • the pharmaceutical formulation can be administered by oral means or other suitable means.
  • Yet another embodiment is a method of treating ovarian cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating colon cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating breast cancer in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the pharmaceutical formulation of the present invention. in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating leukemia in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating colon cancer, before or after surgical resection and/or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention.
  • Yet another embodiment is a method of treating cancer, before or after surgical resection and/or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention, including adjunctive therapy to treat nausea, with or without dexamethasone.
  • Yet another embodiment is a method of treating cancer, before or after surgical resection and or radiation therapy, in a subject (e.g., a human) in need thereof by administering to the subject an effective amount of the compound or the pharmaceutical formulation of the present invention, including adjunctive therapy with one or more additional therapeutic agents, or their pharmaceutically acceptable salts thereof.
  • additional therapeutic agents include cytotoxic agents (such as for example, but not limited to, DNA interactive agents (such as cisplatin or doxorubicin)); taxanes (e.g.
  • topoisomerase II inhibitors such as etoposide
  • topoisomerase I inhibitors such as irinotecan (or CPT-11), camptostar, or topotecan
  • tubulin interacting agents such as paclitaxel, docetaxel or the epothilones
  • hormonal agents such as tamoxifen
  • thymidilate synthase inhibitors such as 5-fluorouracil or 5-FU
  • anti-metabolites such as methoxtrexate
  • alkylating agents such as temozolomide, cyclophosphamide
  • Farnesyl protein transferase inhibitors such as, SARASARTM.
  • anti-cancer also known as anti-neoplastic
  • anti-cancer agents include but are not limited to Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin (ELOXATIN®.
  • Pentostatine Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17 ⁇ -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin,
  • such combination products employ the compounds of this invention within the dosage range described herein (or as known to those skilled in the art) and the other pharmaceutically active agents or treatments within its dosage range.
  • the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108, 2897).
  • the compounds of the invention may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate.
  • the invention is not limited in the sequence of administration; compounds of Formula (I) may be administered either prior to or after administration of the known anticancer or cytotoxic agent.
  • cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of administration with anticancer agents. Cancer Research, (1997) 57, 3375. Such techniques are within the skills of persons skilled in the art as well as attending physicians.
  • any of the aforementioned methods may be augmented by administration of fluids (such as water), loop diuretics, one or more of a chemotherapeutic or antineoplastic agent, such as leucovorin and fluorouracil, and an adjunctive chemotherapeutic agent (such as filgrastim and erythropoietin), or any combination of the foregoing.
  • fluids such as water
  • loop diuretics one or more of a chemotherapeutic or antineoplastic agent, such as leucovorin and fluorouracil
  • an adjunctive chemotherapeutic agent such as filgrastim and erythropoietin
  • Yet another embodiment is a method for administering a compound of the instant invention to a subject (e.g., a human) in need thereof by administering to the subject the pharmaceutical formulation of the present invention.
  • a subject e.g., a human
  • Yet another embodiment is a method of preparing a pharmaceutical formulation of the present invention by mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable additives or excipients.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as an inert compressed gas, e.g. nitrogen.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compounds of this invention may also be delivered subcutaneously.
  • the compound is administered orally or intravenously.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 1000 mg, preferably from about 1 mg to about 500 mg, more preferably from about 1 mg to about 250 mg, still more preferably from about 1 mg to about 25 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • a typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.
  • Another aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to the invention and a cell rescuing agent.
  • the cell rescuing agent is selected from the group consisting of nicotinamide, nicotinamide mononucleotide (NMN) and nicotinic acid.
  • Patient includes both human and animals.
  • “Mammal” means humans and other mammalian animals.
  • inhibitor refers to a molecule such as a compound, a drug, an enzyme activator or a hormone that blocks or otherwise interferes with a particular biologic activity.
  • an “effective amount” or “therapeutically effective amount” refer to a sufficient amount of the agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an “effective amount” for therapeutic use is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease.
  • An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • the expression “effective amount” generally refers to the quantity for which the active substance has therapeutic effects.
  • the active substance is the inhibitor of the formation of Nicotinamide phosphoribosyltransferase (NAMPT).
  • the terms “treat” or “treatment” are synonymous with the term “prevent” and are meant to indicate a postponement of development of diseases, preventing the development of diseases, and/or reducing severity of such symptoms that will or are expected to develop.
  • these terms include ameliorating existing disease symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material which is not biologically or otherwise substantially undesirable, i.e., the material may be administered to an individual without causing any substantially undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • Carrier materials or what are also referred to as “excipients” include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility and the release profile properties of the desired dosage form.
  • exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like.
  • “Pharmaceutically compatible carrier materials” may comprise, e.g., acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, and the like. See, e.g., Hoover, John E., Remington's Pharmaceutical Sciences , Mack Publishing Co., Easton, Pa. 1975.
  • the term “subject” encompasses mammals and non-mammals.
  • mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish and the like.
  • the mammal is a human.
  • alkyl means a straight chain or branched saturated chain having from 1 to 10 or 1 to 6 (C 1 -C 6 ) carbon atoms.
  • Representative saturated alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopent
  • alkyl group can be unsubstituted or substituted.
  • Alkyl groups containing three or more carbon atoms may be straight, branched or cyclized.
  • lower alkyl means an alkyl having from 1 to 6 carbon atoms.
  • an “alkenyl group” includes an unbranched or branched hydrocarbon chain having one or more double bonds therein.
  • the double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group.
  • Illustrative alkenyl groups include, but are not limited to, (C 2 -C 8 ) or (C 2 -C 6 ) alkenyl groups, such as ethylenyl, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl and the like.
  • An alkenyl group can be unsubstituted or substituted.
  • hydroxyalkyl denotes an alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a hydroxy group.
  • hydroxyalkyl include, but are not limited to, meththyl, ethyl propyl, isopropyl, isobutryl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by OH, as well as those hydroxyalkyl groups specifically illustrated b the examples herein below.
  • alkynyl group includes an unbranched or branched hydrocarbon chain having one or more triple bonds therein.
  • the triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group.
  • Suitable alkynyl groups include, but are not limited to, (C 2 -C 6 ) alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, 4-butyl-2-hexynyl and the like.
  • An alkynyl group can be unsubstituted or substituted.
  • haloalkyl denotes an alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
  • haloalkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by Cl, F, Br or I atom(s), as well as those haloalkyl groups specifically illustrated by the examples herein below.
  • haloalkyl groups are monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3,-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, trifluoromethyl.
  • trifluoromethyl include CF 3 , SO 2 , and CO 2 H, respectively.
  • oxo means a ⁇ O group
  • alkylhydroxy or hydroxyalkyl means an alkyl group as defined above, wherein at least one of the hydrogen atoms of the alkyl group is replaced by an OH group.
  • alkoxy as used herein includes —O-(alkyl), wherein alkyl is defined above.
  • haloalkoxy denotes an alkoxy group as defined above wherein at least one of the hydrogen atoms of the alkoxy group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
  • hydroxyalkoxy means an alkoxy group as defined herein, wherein at least one of the hydrogen atoms of the alkoxy group is replaced by an OH group.
  • aminoalkyl as used herein means a group having one or more nitrogen atoms and one or more alkyl groups as defined above on the nitrogen.
  • “Aralkyl” or “arylalkyl” means an aryl-alkyl-group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
  • Heteroarylalkyl means a heteroaryl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core.
  • suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.
  • Heterocyclylalkyl means a heterocyclyl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core.
  • suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
  • variable e.g., aryl, heterocycle, R 2 , etc.
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • N-oxide(s) forms with a N atom member of said heteroaryl denotes a heterorayl group containing a nitrogen atom that forms a N-oxide.
  • N-oxide(s) forms with a N atom member of said heteroaryl denotes a heterorayl group containing a nitrogen atom that forms a N-oxide.
  • Illustrative and non limiting examples of such N-oxides are:
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • deuterium as used herein means a stable isotope of hydrogen having odd numbers of protons and neutrons.
  • halo as used herein means a substituent having at least one halogen selected from fluorine, chlorine, bromine, and iodine.
  • cyano as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
  • amino as used herein means a substituent containing at least one nitrogen atom.
  • aminoalkoxy as used herein means a substituent having at least one amino group and at least one alkoxy group.
  • aryloxy as used herein means a substituent of the form Ar—O— where Ar is an aryl group as defined herein.
  • benzyloxy denotes a benzyl-O— group.
  • arylakenyl denotes an aryl group, as defined herein, attached to the rest of the molecule by an alkenyl group as defined herein.
  • cycloalkylalkoxy- denotes a cycloalkyl group as defined herein, attached to the rest of the molecule by an alkoxy group as defined herein.
  • methylenedioxy as used herein means a functional group with the structural formula —O—CH 2 —O— which is connected to the molecule by two chemical bonds via the oxygens.
  • alkoxyalkyl means -(alkyl)-O-(alkyl), wherein each “alkyl” is independently an alkyl group defined above.
  • (alkoxyalkyl)amino as used herein means a substituent having at least one alkoxyalkyl group as defined above and at least one amino group as defined above.
  • spirocycloalkyl as used herein means a spiro group (containing no heteroatom) linked in a spiro manner to a cycloalkyl group.
  • a non-limiting example would be the moiety shown below:
  • spiroheterocycloalkyl as used herein means a spiro group (containing no heteroatom) linked in a spiro manner to a heterocycloalkyl group.
  • a non-limiting example would be the moiety shown below:
  • heterospiroheterocycloalkyl as used herein means a spiro group (containing a hetero atom such O, N or S) linked in a spiro manner to a heterocycloalkyl group.
  • a hetero atom such O, N or S
  • a non-limiting example would be the moiety shown below:
  • Aryl as used herein means a monovalent aromatic hydrocarbon radical of 6-20 or 6-10 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • Aryl includes bicyclic radicals comprising an aromatic ring fused to a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring.
  • Exemplary aryl groups include, but are not limited to, radicals derived from benzene, naphthalene, anthracene, biphenyl, indene, indane, 1,2-dihydronapthalene, 1,2,3,4-tetrahydronapthalene, and the like.
  • Aryl groups may be optionally substituted independently with one or more substituents described herein.
  • Illustrative examples of aryl groups include, but are not limited to, the following moieties:
  • Illustrative substituted aryls include:
  • heteroaryl refers to a monocyclic, or fused polycyclic, aromatic heterocycle (ring structure having ring atoms selected from carbon atoms as well as nitrogen, oxygen, and sulfur heteroatoms) having from 3 to 24 ring atoms per ring.
  • heteroaryl as used herein also includes monovalent aromatic radical of a 5-, 6-, or 7-membered ring and includes fused ring systems (at least one of which is aromatic) of 5-10 atoms containing at least one heteroatom independently selected from nitrogen, oxygen, and sulfur.
  • heteroaryl groups include, but are not limited to, pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophen
  • Heteroaryl groups may be optionally substituted independently with one or more substituents described herein.
  • 5 or 6 membered heteroaryl can be selected from the group consisting of optionally substituted pyridinyl, pyrimidinyl, thiazolyl, imidazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridinone and benzimidazolyl.
  • carbon bonded heterocycles and heteroaryls are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
  • nitrogen bonded heterocycles and heteroaryls are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of an isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
  • heteroaryl and substituted heteroaryl groups include, but are not limited to the following moieties:
  • bicyclic heteroaryl means a structure having atoms arranged in two rings fused together with at least two atoms common to each ring, and at least one of the rings being a heteroaryl ring.
  • Non limiting examples of bicyclic heteroaryl comprise 5 to 13 or 5 to 10 membered bicyclic heteroaryl-groups comprising 1, 2, 3 or 4 heteroatoms independently selected from N, S, or O:
  • bicyclic heteroaryls include but are not limited to:
  • cycloalkyl refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle having from 3 to 24 (C 3 -C 24 ), 3 to 12(C 3 -C 12 ), 3 to 10 (C 3 -C 10 ) or 3 to 6 (C 3 -C 6 ) ring atoms per ring.
  • Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
  • heterocycloalkyl refers to a monocyclic, or fused or spiro, polycyclic, ring structure that is saturated or partially saturated and has from 3 to 24 ring atoms per ring selected from C atoms and N, O, and S heteroatoms.
  • ring atoms per ring selected from C atoms and N, O, and S heteroatoms.
  • Illustrative examples of heterocycloalkyl and substituted heterocycloalkyl groups include, but are not limited to:
  • Numerical ranges are intended to include sequential whole numbers. For example, a range expressed as “from 0 to 4” would include 0, 1, 2, 3 and 4.
  • substituted means that the specified group or moiety bears one or more suitable substituents.
  • cycloalkyloxy refers to alkyl being the point of attachment to the core while cycloalkyl is attached to alkyl via the oxy group.
  • adjunctive chemotherapeutic agent generally refers to agents which treat, alleviate, relieve, or ameliorate the side effects of chemotherapeutic agents. Such agents include those which modify blood cell growth and maturation. Examples of adjunctive chemotherapeutic agents include, but are not limited to, filgrastim and erythropoietin. Other such adjunctive chemotherapeutic agents include those which inhibit nausea associated with administration of the chemotherapeutic agents, such as a 5-HT 3 receptor inhibitor (e.g., dolansetron, granisetron, or ondansetron), with or without dexamethasone.
  • a 5-HT 3 receptor inhibitor e.g., dolansetron, granisetron, or ondansetron
  • chemotherapeutic agent and “antineoplastic agent” generally refer to agents, which treat, prevent, cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect malignancies and their metastasis.
  • agents also known as “antineoplastic agents” include, but are not limited to, prednisone, fluorouracil (e.g., 5-fluorouracil (5-FU)), anastrozole, bicalutamide, carboplatin, cisplatin, chlorambucil, cisplatin, carboplatin, docetaxel, doxorubicin, flutamide, interferon-alpha, letrozole, leuprolide, megestrol, mitomycin, oxaliplatin, paclitaxel, plicamycin (MithracinTM), tamoxifen, thiotepa, topotecan, valrubicin, vinylastin, vincristine, and any combination of
  • NAMPT nicotinamide adenyl dinucleotide
  • NAMPT nicotinamide phosphoribosyltransferase
  • a physiologically acceptable carrier or excipient is a formulation to which the compound can be added to dissolve it or otherwise facilitate its administration.
  • the dosage forms of the present invention may contain a mixture of one or more compounds of this invention, and may include additional materials known to those skilled in the art as pharmaceutical excipients.
  • Such pharmaceutical excipients include, for example, the following: Stabilizing additives may be incorporated into the delivery agent solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution.
  • the stabilizing additives may be employed at a concentration ranging from about 0.1 and 5% (W/V), preferably about 0.5% (W/V).
  • Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, carboxylic acids and salts thereof, and polylysine.
  • the preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
  • Acidifying agents acetic acid, glacial acetic acid, citric acid, fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaric acid
  • Aerosol propellants butane, dichlorodifluoro-methane, dichlorotetrafluoroethane, isobutane, propane, trichloromonofluoromethane
  • Air displacements carbon dioxide, nitrogen
  • Alcohol denaturants denatonium benzoate, methyl isobutyl ketone, sucrose octacetate
  • Alkalizing agents strong ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine
  • Anticaking agents see glidant
  • Antifoaming agents (dimethicone, simethi
  • the compounds of the invention can form salts which are also within the scope of this invention.
  • Reference to a compound of the Formula herein is understood to include reference to salts thereof, unless otherwise indicated.
  • the term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • zwitterions inner salts may be formed and are included within the term “salt(s)” as used herein.
  • Salts of the compounds of the Formulas may be formed, for example, by reacting a compound of Formulas with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
  • Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
  • dimethyl, diethyl, and dibutyl sulfates dimethyl, diethyl, and dibutyl sulfates
  • long chain halides e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides
  • aralkyl halides e.g. benzyl and phenethyl bromides
  • esters of the compounds of the invention are also considered to be part of the invention.
  • Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C 1-4 alkyl, or C 1-4 alkoxy or amino); (2)sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example
  • Prodrugs and solvates of the compounds of the invention are also contemplated herein.
  • a discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press.
  • the term “prodrug” means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of the instant Formulas or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
  • prodrugs are described by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
  • a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (C 1 -C 8 )alkyl, (C 2 -C 12 )alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbon
  • a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C 1 -C 6 )alkanoyloxymethyl, 1-((C 1 -C 6 )alkanoyloxy)ethyl, 1-methyl-1-((C 1 -C 6 )alkanoyloxy)ethyl, (C 1 -C 6 )alkoxycarbonyloxymethyl, N—(C 1 -C 6 )alkoxycarbonylaminomethyl, succinoyl, (C 1 -C 6 )alkanoyl, ⁇ -amino(C 1 -C 4 )alkanyl, arylacyl and ⁇ -aminoacyl, or ⁇ -aminoacyl- ⁇ -aminoacyl, where each ⁇ -aminoacyl group is independently selected from the naturally occurring L-amino acids, P(
  • a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR′-carbonyl where R and R′ are each independently (C 1 -C 10 )alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural ⁇ -aminoacyl or natural ⁇ -aminoacyl, —C(OH)C(O)OY 1 wherein Y 1 is H, (C 1 -C 6 )alkyl or benzyl, —C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and Y 3 is (C 1 -C 6 )alkyl, carboxy(C 1 -C 6 )alkyl, amino(C 1 -C 4 )alkyl or mono-
  • R-carbonyl RO-carbonyl
  • One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
  • “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H 2 O.
  • One or more compounds of the invention may optionally be converted to a solvate.
  • Preparation of solvates is generally known.
  • M. Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
  • Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun, 603-604 (2001).
  • a typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
  • Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
  • the compounds of the invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the various Formulas as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers. For example, if a compound of the various Formulas incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • converting e.g., hydrolyzing
  • some of the compounds of the various Formulas may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention.
  • Enantiomers
  • All stereoisomers for example, geometric isomers, optical isomers and the like
  • of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs
  • those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
  • salt is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
  • the present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 25 S, 18 F, and 36 Cl, respectively.
  • Certain isotopically-labelled compounds of the various Formulas are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Isotopically labelled compounds of the various Formulas can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
  • Benefits of the present invention include oral administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intravenous administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intraperitoneal administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intramural administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intramuscular administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include subcutaneous administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intra-tumor administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include intrathecal administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include subdural administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present invention include periorbital administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • the present invention has important implications for the design of novel treatment strategies for patients with cancer, including leukemias and solid tumors, inflammatory diseases, osteoporosis, atherosclerosis; irritable bowel syndrome and other conditions disclosed herein or that are known to those skilled in the art.
  • An aspect of the present invention concerns compounds disclosed herein.
  • An aspect of the present invention concerns compounds which are or can be inhibitors of the formation of nicotinamide phosphoribosyltransferase.
  • An aspect of the present invention concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of tumors.
  • An aspect of the present invention concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer.
  • An aspect of the present invention concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer, where the cancer is selected from leukemia, lymphoma, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer and Hodgkin's disease.
  • the present invention also describes one or more methods of synthesizing the compounds of the present invention.
  • the invention also describes one or more uses of the compounds of the present invention.
  • the invention also describes one or more uses of the compounds of the present invention with an adjunctive agent such as use with TNF, GCSF, or other chemotherapeutic agents
  • the invention also describes one or more uses of the pharmaceutical compositions of the present invention.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of inflammatory diseases.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of inflammatory diseases, such as Irritable Bowel Syndrome or Inflammatory Bowel Disease.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease of the bone such as osteoporosis.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease of the cardiovascular system, such as atherosclerosis.
  • An aspect of the present invention concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease or a condition caused by an elevated level of NAMPT.
  • Such disease or condition is one or more selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spodylitis, graft-versus-host disease, Alzheimer's disease, cerebrovascular accident, atherosclerosis, diabetes, glomerulonephiritis, metabolic syndrome, non-small cell lung cancer, small cell
  • the compounds of the invention can be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
  • proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
  • the compounds can be useful in the treatment of a variety of cancers, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and
  • tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma and schwannomas; and other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
  • the compounds of the invention may induce or inhibit apoptosis.
  • the compounds of the invention may also be useful in the chemoprevention of cancer.
  • Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.
  • a further aspect of the invention is a method of inhibiting a NAMPT pathway in an animal, said method comprising administering to said animal a pharmaceutically acceptable amount of a compound of the invention to an animal in need thereof.
  • a further aspect of the invention is a pharmaceutical formulation comprising a compound of the invention.
  • Another embodiment of the invention comprises a pharmaceutical formulation of the invention, wherein the pharmaceutical formulation, upon administration to a human, results in a decrease in tumor burden.
  • Still another embodiment of the invention is a pharmaceutical formulation, further comprising one or more of an antineoplastic agent, a chemotherapeutic agent, or an adjunctive chemotherapeutic agent.
  • the pharmaceutical formulations of the invention may further comprise a therapeutic effective amount of an adjunctive chemotherapeutic agent.
  • the adjunctive chemotherapeutic agent may be an agent, which modifies blood cell growth and maturation.
  • Non-limiting examples of adjunctive chemotherapeutic agent are filgrastim, pegfilgrastim and erythropoietin.
  • the invention is also directed to a method of treating or preventing a disorder associated with excessive rate of growth of cells in a mammal comprising administering to the mammal an effective amount of the pharmaceutical formulation of the invention.
  • disorder include cancer or metastasis from malignant tumors.
  • Another aspect of the invention is a method of inhibiting tumor cell growth and rate of division in a mammal with cancer, or other disorder associated with abnormally dividing cells comprising administering to the mammal an effective amount of the pharmaceutical formulation of this invention.
  • Another embodiment of the invention is a method of treating bone pain due to excessive growth of a tumor or metastasis to bone in a mammal in need thereof comprising administering to the mammal an effective amount of the pharmaceutical formulation of this invention.
  • Still another embodiment of the invention is a method for administering a NAMPT-inhibitor-containing compound to a mammal in need thereof comprising administering to the mammal the pharmaceutical formulation of the invention.
  • the mammal is a human.
  • a further embodiment of the invention is a method of preparing a pharmaceutical formulation comprising mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable excipients or additives.
  • the invention is also directed to methods of synthesizing compounds of the present invention.
  • the invention is directed to pharmaceutical compositions comprising one or more compounds as described herein and pharmaceutically acceptable salts, sovates, esters, prodrugs or isomers thereof.
  • the invention further relates to molecules which are useful in inhibiting the enzyme nicotinamide phosphoribosyltransferase (NAMPT) and pharmaceutically acceptable salts, solvates, esters, prodrugs or isomers thereof.
  • NAMPT nicotinamide phosphoribosyltransferase
  • An aspect of the invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals having a compound of Formula I
  • Another aspect of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals having a compound of the Formula I, where X,L,Q, Ar 1 and A are as defined in Formula I and R 1 is selected from H, a straight or branched C 1 to C 7 alkyl, straight or branched C 1 to C 7 alkoxy, straight or branched C 1 to C 4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, arylalkyl-, heteroarylalkyl-, heterocycloalkylalkyl-, cycloalkylalkyl-, hydroxyalkyl-, alkoxyalkyl-, spiroheterocycloalkyl and heterospiroheterocycloalkyl, wherein the heteroatoms of said heteroaryl and heterocycloalkyl in the moieties above are independently selected from one or more N, O and S, with the proviso that
  • R 2 is selected from H, a straight or branched C 1 to C 7 alkyl, straight or branched C 1 to C 7 alkoxy, straight or branched C 1 to C 4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, arylalkyl-, heteroarylalkyl-, heterocycloalkylalkyl-, cycloalkylalkyl-, hydroxyalkyl-, alkoxyalkyl-, heterospirocycloalkyl and heterospiroheterocycloalkyl, wherein the heteroatoms of said heteroaryl and heterocycloalkyl in the moieties above are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein R 2 can be either unsubstituted or optionally independently (i) either substituted with one or more substituents which can be the same or different and are independently selected from the group
  • the compound of Formula I is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridine-4-ylmethyl)thiourea or 3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • Another aspect of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals having a compound of the Formula I, where X,L,Q, Ar 1 and A are as defined in Formula I and R 1 and R 2 are joined together to form, along with the N they are shown attached to in the formula, a C 3 -C 8 heterocycloalkyl, a C 3 -C 8 heterocycloalkenyl, a fused bicyclic heterocycloalkyl, a fused tricyclic heterocycloalkyl, spiroheterocyclaolkyl or a heterospiroheterocycloalkyl, wherein each of said heterocycloalkyl, heterocycloalkenyl, spiroheterocyclaolkyl and heterospiroheterocycloalkyl can optionally contain one or more heteroatoms in addition to the N atom they are shown attached to in the formula, said heteroatoms being selected from N, S and O,
  • R 3 is H, alkyl or arylalkyl with the proviso that the compound is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridine-4-ylmethyl)thiourea or 3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • the invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, ester or isomers thereof.
  • aryl, heteroaryl, heterocycloalkyl, cycloalkyl, spiroheterocycloalkyl and heterospiroheterocycloalkyl as well as their representative moieties in these embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier. Any one or more of the embodiments relating to Formula I below can be combined with one or more other embodiments of Formula I.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is aryl, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is heteroaryl, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is heterocycloalkyl, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is aryl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is heteroaryl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is heterocycloalkyl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is aryl substituted as shown under Formula I, IA or IB, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is heteroaryl substituted as shown under Formula I, IA or IB, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 is heterocycloalkyl substituted as shown under Formula I, IA or IB, and z, X, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, X is a straight chain alkyl, and Ar 1 , z, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, X is a branched chain alkyl, and Ar 1 , z, L, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, L is —N(H)—C(O)—N(H)—, and Ar 1 , z, X, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Q is —S(O 2 )—, and Ar 1 , z, X, A, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 3 is H, and Ar 1 , z, X, A, Q, R 1 , and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 3 is alkyl, and Ar 1 , z, X, A, Q, R 1 , and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 3 is arylalkyl, and Ar 1 , z, X, A, Q, R 1 , and R 2 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, z is 0, and Ar 1 , X, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, z is 1, and Ar 1 , X, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, z is 2, and Ar 1 , X, A, Q, R 1 , R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, and Ar 1 , z, X, A, Q, R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 2 is H, and Ar 1 , z, X, A, Q, R 2 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are H, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is alkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is aryl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heteroaryl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heterocycloalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is cycloalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is alkoxy, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is hydroxyalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is aryloxy, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is arylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heteroarylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is cycloalkylalkyl-, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heterocycloalkylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is alkoxyalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is spiroheterocycloalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is spiroheterocycloalkylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is alkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is aryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heteroaryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heterocycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is cycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is aryloxy with the aryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is arylalkyl with the aryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heteroarylalkyl with the heteroaryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is cycloalkylalkyl- with the cycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heterocycloalkylalkyl with the heterocycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is spiroheterocycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is spiroheterocycloalkylalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is alkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is aryl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heteroaryl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heterocycloalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is cycloalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is aryloxy, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is arylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heteroarylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is cycloalkylalkyl-, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heterocycloalkylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is spiroheterocycloalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is spiroheterocycloalkylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is alkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is aryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heteroaryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heterocycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is cycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is aryloxy with the aryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is arylalkyl with the aryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heteroarylalkyl with the heteroaryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is cycloalkylalkyl- with the cycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heterocycloalkylalkyl with the heterocycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is spiroheterocycloalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is spiroheterocycloalkylalkyl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is bicycloheptanyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is cyclopropyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is cyclobutyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is cyclopentyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is cyclopentylmethyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is benzyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is furanyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is furanylmethyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is phenyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is naphthalenyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is biphenylmethyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is biphenyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is tolyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is pyridinyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is unsubstituted, pyridinylmethyl (substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is phenylethyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is benzyl (unsubstituted, substituted or fused as described earlier), R 2 is benzyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is quinolinyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is oxazolyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is indazolyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is dihydrobenzodioxepinyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is pyrazolyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is terrahydronaphthalenyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is isoquinolinyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is oxolanyl (unsubstituted, substituted or fused as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a heterocycloalkyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a heterocycloalkenyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a fused bicyclic heterocycloalkyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a fused tricyclic heterocycloalkyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a spiroheterocycloalkyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a heterospiroheterocycloalkyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a piperidinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a piperazinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a morpholinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, an azapenyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, an azetidinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a oxaazabicyclooctanyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, an azabicycloheptanyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a dihydrobenzoxazinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a dihydroindolyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a thiomorpholinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, an azatricyclotridecapentaenyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, an azaspirodecanyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a terrahydronaphthyridinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, an azabicyclooctanyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a diazepanyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a decahydroquinolyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a diazaspiroundecanyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a terahydroisoquinolinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 , z, X, A, Q, and R 3 are as defined, and R 1 and R 2 are the same or different, wherein said R 1 and R 2 independently are unsubstituted or substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of —C(O)NH 2 , alkyl, —C(O)NH(alkyl), —C(O)N(alkyl) 2 , halo, morpholinyl, alkoxyalkyl-, alkenyl, alkyl, CF 3 , OH, CN, phenyl, isocyano, —N(H)C(O)CH 3 , phenylethyl-, —C(O)CH 3 , phenoxy, —S(O 2 )CH 3 , —S(O 2 )CF 3 , pyr
  • An embodiment of the invention is the provision of a compound of Formula I, where the various moieties are independently selected, Ar 1 , z, X, A, Q, and R 3 are as defined, and R 1 and R 2 are joined together to form, along with the N, a C 3 -C 8 heterocycloalkyl, a C 3 -C 8 heterocycloalkenyl, a fused bicyclic heterocycloalkyl, a fused tricyclic heterocycloalkyl, spiroheterocycloalkyl or a heterospiroheterocycloalkyl, wherein each of said C 3 -C 8 heterocycloalkyl, a C 3 -C 8 heterocycloalkenyl, a fused bicyclic heterocycloalkyl, a fused tricyclic heterocycloalkyl, spiroheterocycloalkyl or a heterospiroheterocycloalkyl independently is unsubstituted or bears one or more
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, R 2 is aryl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, R 2 is heteroaryl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, R 2 is heterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, R 2 is spiroheterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, R 2 is heterospiroheterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is aryl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heteroaryl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is spiroheterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heterospiroheterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, R 2 is aryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, A is phenyl, R 2 is heteroaryl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, A is phenyl, R 2 is heterocycloalkyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, A is phenyl, R 2 is spiroheterocycloalkyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, A is phenyl, R 2 is heterospiroheterocycloalkyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is aryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heteroaryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is phenyl, R 1 is H, R 2 is aryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is phenyl, R 1 is H, A is phenyl, R 2 is heteroaryl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is phenyl, R 1 is H, A is phenyl, R 2 is heterocycloalkyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is phenyl, R 1 is H, A is phenyl, R 2 is spiroheterocycloalkyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is phenyl, R 1 is H, A is phenyl, R 2 is heterospiroheterocycloalkyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is aryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heteroaryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridyl, R 1 is H, R 2 is aryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridyl, R 1 is H, R 2 is heteroaryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridyl, R 1 is H, R 2 is heterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridyl, R 1 is H, R 2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridyl, R 1 is H, R 2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is aryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is heteroaryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is heterocycloalkyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is pyridinylmethyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is pyridinylmethyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is alkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is hydroxyalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is phenylalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is cycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is oxolanyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is quinolinyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is oxazolyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is spiroheterocycloakyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is tetrahydronaphthalenyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is dihydrobenzodioxepinyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is pyridinyl, R 1 is H, R 2 is alkoxyalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is piperidinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is morpholinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is piperazinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azapenyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azetidinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is oxaazabicyclooctanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azabicycloheptanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is dihydrobenzoxazinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is dihydroindolyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is thiomorpholinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azatricyclotridecapentaenyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azaspirodecanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azaspiroundecanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is tetrahydronaphthyridinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azabicyclooctanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is diazepanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is decahydroquinolinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is diazaspiroundecanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is tetrahydroisoquinolinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is piperidinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is morpholinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is piperazinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azapenyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azetidinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is oxaazabicyclooctanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azabicycloheptanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is dihydrobenzoxazinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is dihydroindolyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is thiomorpholinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azatricyclotridecapentaenyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azaspirodecanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azaspiroundecanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is tetrahydronaphthyridinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azabicyclooctanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is diazepanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is decahydroquinolinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is diazaspiroundecanyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is tetrahydroisoquinolinyl, and z, X, L, A, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is piperidinyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is morpholinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is piperazinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azapenyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azetidinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is oxaazabicyclooctanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azabicycloheptanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is dihydrobenzoxazinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is dihydroindolyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is thiomorpholinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azatricyclotridecapentaenyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azaspirodecanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azaspiroundecanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic), where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is tetrahydronaphthyridinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azabicyclooctanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is diazepanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is decahydroquinolinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is diazaspiroundecanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is tetrahydroisoquinolinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is piperidinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is morpholinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is piperazinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azapenyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azetidinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is oxaazabicyclooctanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azabicycloheptanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is dihydrobenzoxazinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is dihydroindolyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is thiomorpholinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azatricyclotridecapentaenyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azaspirodecanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azaspiroundecanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is tetrahydronaphthyridinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is azabicyclooctanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is diazepanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is decahydroquinolinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is diazaspiroundecanyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula I where NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, NR 1 R 2 is tetrahydroisoquinolinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • Another embodiment of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals having a compound of the Formula II:
  • aryl, heteroaryl, heterocycloalkyl, cycloalkyl, spiroheterocycloalkyl and heterospiroheterocycloalkyl as well as their representative moieties in these embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier. Any one or more of the embodiments relating to Formula II below can be combined with one or more other embodiments of Formula II.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heterocycloalkyl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heterocycloalkyl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl substituted as shown under Formula II, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl substituted as shown under Formula II, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heterocycloalkyl substituted as shown under Formula II, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is H, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a straight chain alkyl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a branched chain alkyl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is H, n is 1, and z, X, L, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a straight chain alkyl, n is 1, and z, X, L, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a branched chain alkyl, n is 1, and z, X, L, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, and z, X, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, and z, X, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, and z, X, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is aryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, and z, X, L, n, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, and z, X, L, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, and z, X, L, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, and z, X, L, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(nd z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, and z, Ar 2 , R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, Ar 2 is aryl, and z, X, L, n, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, and z, X, L, n, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, and z, X, L, n, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, Ar 2 is aryl, and z, X, L, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, n is 1, and z, X, L, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, n is 1, and z, X, L, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound, of Formula II where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, n is 1, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, n is 1, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, n is 1, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, n is 1, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, Ar 2 is heteroaryl, R 1 is aryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound, of Formula II where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, n is 1, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, n is 1, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, Ar 2 is heteroaryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, n is 1, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, Ar 2 is aryl, n is 1, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O 2 )—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —S(O)—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —C(O)—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is —N(H)—C(O)—N(H)—, X is —O—, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is selected from the group consisting of pyridinyl, imidazopyridinyl, pyrazolyl, quinolinyl and thienopyridinyl. Each of these moieties may be unsubstituted or optionally independently substituted with one or more groups which can be the same or different and are independently selected from the group consisting of —NH 2 , —N(alkyl) 2 , (alkoxyalkyl)oxy-, and pyrazolyl.
  • An embodiment of the invention is the provision of a compound of Formula II, where the various moieties are independently selected, R 1 is selected from the group consisting of cyclopentyl, CF 3 , phenyl, naphthalenyl, pyrimidinyl, oxazolyl, 8-oxatricyclotridecahexaenyl and thienyl.
  • Each of these moieties may be unsubstituted or optionally independently substituted with one or more groups which can be the same or different and are independently selected from the group consisting of —C(O)NH 2 , —S(O 2 )CH 3 , F, Cl, Br, methylenedioxy, CF 3 , OCF 3 , alkyl, alkoxy, pyrazolyl, C(O)CH 3 and phenoxy.
  • Another aspect of this invention is the provision of compounds, compositions, kits, and antidotes for the NAMPT pathway in mammals derived from compounds of Formula I and Formula II and having the Formula III:
  • Ar 1 is 5 to 12 membered heteroaryl comprising 1, 2, 3 or 4 heteroatom(s) independently selected from N, S or O, wherein said heteroaryl is unsubstituted or substituted by one or more R a selected from the group consisting of —NH 2 , oxo, halo, haloalkyl, —NH(CO)O-alkyl, —C(O)NH 2 and 3,4-dihydroxy-5-methyltetrahydrofurane; and wherein said heteroaryl can comprise one or more N-oxide(s) formed with a N atom member of said heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
  • Ar 2 is aryl or 5 or 6 membered heteroaryl comprising 1, 2, 3 or 4 heteroatom(s) independently selected from N, S or O;
  • R is H, a straight or branched C 1 -C 6 alkyl, or arylalkyl
  • R 1 is —NR 3 R 4 wherein R 3 is H, alkyl or —S(O) 2 alkyl and R 4 is alkyl, hydroxyalkyl, —S(O) 2 alkyl, —(CH 2 ) q cycloalkyl, —(CH 2 ) q heterocycloalkyl, aryl, arylalkyl-, —(CH 2 ) q heteroaryl; haloalkyl, cycloalkyl; aryl; heterocycloalkyl; or heteroaryl; wherein:
  • R 2 is O or absent
  • R b and R c are independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxy, aryl, alkoxyalkyl, —S(O) 2 alkyl and cycloalkyl or R b and R c can form a 5 or 6 membered heterocycloalkyl group together with the nitrogen atom to which they are attached, wherein said heterocycloalkyl group may contain one or more additional heteroatom(s) selected from N, S or O;
  • n 0, or 1;
  • q 0, 1 or 2;
  • the compound of Formula I is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridine-4-ylmethyl)thiourea or 3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • this invention discloses compounds of Formula III and pharmaceutically acceptable salts, solvates, ester or isomers thereof.
  • aryl, heteroaryl, heterocycloalkyl, cycloalkyl, spiroheterocycloalkyl and heterospiroheterocycloalkyl as well as their representative moieties in these embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier. Any one or more of the embodiments related to Formula III below can be combined with one or more other embodiments of Formula III.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and Ar 2 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and Ar 2 is phenyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and Ar 2 has the following formula:
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and Ar 1 is pyridine.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and Ar 1 has the following formula:
  • R a is selected from the group consisting of —NH 2 , oxo, halo, haloalkyl, —NH(CO)O-alkyl, —C(O)NH 2 and 3,4-dihydroxy-5-methyltetrahydrofurane.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and Ar 1 has the formula of:
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and n is 1.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and n is 1.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1 and Ar 2 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1 and Ar 2 is phenyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and Ar 2 is phenyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and Ar 2 has the following formula:
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R is H.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R is H.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, n is 1 and R is H.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R is H.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, n is 1, Ar 2 is phenyl and R is H.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R is H.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is —NR 3 R 4 wherein R 3 is H, alkyl or —S(O) 2 alkyl and R 4 is alkyl, hydroxyalkyl, —S(O) 2 alkyl, —(CH 2 ) q cycloalkyl, —(CH 2 ) q heterocycloalkyl, aryl, arylalkyl-, —(CH 2 ) q heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is —NR 3 R 4 wherein R 3 is H and R 4 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is —NR 3 R 4 wherein R 3 is H and R 4 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is —NR 3 R 4 wherein R 3 is H and R 4 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is —NR 3 R 4 wherein R 3 is H and R 4 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is —NR 3 R 4 wherein R 3 is H and R 4 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is —NR 3 R 4 wherein R 3 is H and R 4 is aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is haloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is haloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is haloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is haloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is haloalkyl.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is haloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is haloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is haloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted C 6 -C 10 -aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted C 6 -C 10 -aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 6 -C 10 -aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 6 -C 10 -aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted C 6 -C 10 -aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 6 -C 10 -aryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted C 6 -C 10 -aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted C 6 -C 10 -aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 6 -C 10 -aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 6 -C 10 -aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted C 6 -C 10 -aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted C 6 -C 10 -aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is aryl and R 1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is aryl and R 1 is unsubstituted or substituted heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted heteroaryl.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3′-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.0 2,7 ]trideca-1(9),2(7),
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3′-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.0 2,7 ]trideca
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3′-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.0 2,7 ]-tri
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3′-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, and R 1 is unsubstituted or substituted unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3′-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatri
  • An embodiment of the invention is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1, Ar 2 is phenyl and R 1 is unsubstituted or substituted unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3′-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole
  • Another embodiment of the invention is the provision of a compound of Formula III where Ar 1 is pyridine, n is 1, Ar 2 is phenyl and the Formula becomes Formula III A:
  • R 1 and R a are as defined in Formula III with the proviso that the compounds are not N-[4-(phenylsulfonyl)phenyl]-N′-(3-pyridinylmethyl)urea, N,N-diethyl-4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide, or 4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide.
  • Another embodiment of the invention is compounds of Formula III where Ar 2 is
  • phenyl and Ar 1 has the structure of and the formula becomes Formula IIIB
  • An embodiment of the invention is compounds of Formula IIIB, wherein R 1 is —NR 3 R 4 wherein R 3 is H, alkyl or —S(O) 2 alkyl and R 4 is alkyl, hydroxyalkyl, —S(O) 2 alkyl, —(CH 2 ) q cycloalkyl, —(CH 2 ) q heterocycloalkyl, aryl, arylalkyl-, —(CH 2 ) q heteroaryl.
  • Another embodiment of the invention is compounds of Formula IIIB, where R 1 is NR 3 R 4 wherein R 3 is H and R 4 is aryl.
  • Another embodiment of the invention is compounds of Formula IIIB wherein R 1 is haloalkyl.
  • Another embodiment of the invention is compounds of Formula IIIB wherein R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl.
  • Still another embodiment of the invention is compounds of Formula IIIB, wherein R 1 is unsubstituted or substituted C 3 -C 12 -cycloalkyl and the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • Yet another embodiment of the invention is compounds of Formula IIIB wherein R 1 is unsubstituted or substituted C 6 -C 10 -aryl.
  • a further embodiment of the invention is compounds of Formula III B wherein R 1 is unsubstituted or substituted C 6 -C 10 -aryl and the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • Another embodiment of the invention is compounds of Formula IIIB, wherein R 1 is unsubstituted or substituted heterocycloalkyl.
  • One embodiment of the invention is compounds of Formula III B, wherein R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S
  • the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • Another embodiment of the invention is compounds of Formula IIIB, wherein R 1 is unsubstituted or substituted heteroaryl.
  • R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • Still another embodiment of the invention is compounds of Formula IIIB, wherein R 1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, and the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3′-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.0 2,7 ]-trideca-1(9),2(7),3,5,10,12-hexaene
  • Illustrative compounds of the invention are:
  • the compounds of the present invention can be prepared through numerous routes well-known to those skilled in the art of organic synthesis.
  • compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art.
  • Preferred methods include but are not limited to those methods described below.
  • urea-sulfonamide (IV) can be synthesized by following the steps outlined in Scheme 1.
  • Intermediate II can be obtained by treating I with phosgene, thiophosgene, carbonyldiimidazole, or other such activating group in an inert solvent such as dichloromethane, benzene, or toluene at temperatures ranging from ⁇ 78° C. to 200° C.
  • Intermediate V can be obtained by treating I with 4-nitrophenyl carbonochloridate in an inert solvent such as dichloromethane, benzene, or toluene at temperatures ranging from ⁇ 78° C. to 200° C.
  • the compound of present invention IV can be obtained by treating compound III with either II or V in an organic solvent at temperatures ranging from ⁇ 78° C. to 200° C.
  • urea-sulfone (IV) can be synthesized by following the steps outlined in Scheme 2.
  • Intermediate II can be obtained by treating I with phosgene, thiophosgene, carbonyldiimidazole (or similar reagent) in an inert solvent such as dichloromethane, benzene, or toluene at temperatures ranging from ⁇ 78° C. to 200° C.
  • the compound of present invention IV can be obtained by treating intermediate II with III in an organic solvent at temperatures ranging from ⁇ 78° C. to 200° C.
  • the compound of present invention urea-sulfone IV can also be synthesized by following the steps outlined in Scheme 2A.
  • Intermediate VI can be obtained by treating III with V in an inert solvent such as dichloromethane and benzene at temperatures ranging from ⁇ 78° C. to 200° C.
  • Treatment of VI with agents such as NaBH 4 , NaI, or Na 2 S 2 O 3 in a solvent such as water or THF at temperatures ranging from ⁇ 78° C. to 200° C. gives intermediate VII.
  • Compound IV can be obtained by treating VII and VIII with a suitable transition metal catalyst such as, but not limited to, Pd(PPh 3 ) 4 , palladium(II) acetate, or Cu(OAc) 2 in the presence of a base (eg: K 2 CO 3 , Cs 2 CO 3 , NR 1 R 2 R 3 , NaOR, KOR) in an inert solvent such as N,N-dialkylformamide, N,N-dialkylacetamide, or dichloromethane at temperatures ranging from ⁇ 78° C. to 200° C.
  • a suitable transition metal catalyst such as, but not limited to, Pd(PPh 3 ) 4 , palladium(II) acetate, or Cu(OAc) 2
  • a base eg: K 2 CO 3 , Cs 2 CO 3 , NR 1 R 2 R 3 , NaOR, KOR
  • an inert solvent such as N,N-dialkylformamide, N,N-dialkylacetamide,
  • Triphosgene (41 mg, 0.137 mmol) was dissolved in DCM (5 mL) and cooled to ⁇ 10° C. under N 2 atmosphere. To this cooled solution was added dropwise a mixture of 4-(piperidin-1-ylsulfonyl) aniline (100 mg, 0.416 mmol) and TEA (127 mg, 1.25 mmol) in DCM (5 mL). The mixture was stirred at ⁇ 10° C. for 5 minutes and allowed to warm up to room temperature for 1 hour. A solution of 5-fluoropyridin-3-yl)methanamine (55 mg, 0.50 mmol) and TEA (127 mg, 1.25 mmol) in DCM (5 mL) was then added.
  • the reaction mixture was stirred at room temperature for 16 hours.
  • the mixture was diluted with DCM (25 mL), washed with brine (2 ⁇ 15 mL), dried over MgSO 4 , filtered and concentrated under reduced pressure.
  • the crude was purified by Biotage using 5% MeOH/DCM to afford the desired product as a white amorphous powder.
  • the title compound was prepared following Example 1, substituting pyridin-3-ylmethanamine and 4-(4-morpholinopiperidin-1-ylsulfonyl)aniline for (5-fluoropyridin-3-yl)methanamine and 4-(piperidin-1-ylsulfonyl)aniline, respectively.
  • Triphosgene (41 mg, 0.137 mmol) was dissolved in DCM (5 mL) and cooled to ⁇ 10° C. under N 2 atmosphere. To this cooled solution was added dropwise a mixture of 4-(piperidin-1-ylsulfonyl) aniline (100 mg, 0.416 mmol) and TEA (127 mg, 1.25 mmol) in DCM (5 mL). The mixture was stirred at ⁇ 10° C. for 5 minutes and allowed to warm up to room temperature for 1 hour. A solution of 5-(aminomethyl)picolinonitrile HCl (85 mg, 0.50 mmol) and TEA (2.52 mmol) in DCM (5 mL) was then added.
  • the reaction mixture was stirred at room temperature for 16 hours.
  • the mixture was diluted with DCM (25 mL), washed with brine (2 ⁇ 15 mL), dried over MgSO 4 , filtered and concentrated under reduced pressure.
  • the crude was purified by Biotage using 5% MeOH/DCM to afford the desired product as a white amorphous powder (54 mg, 32.5% yield).
  • Triphosgene (122 mg, 0.412 mmol) was dissolved in DCM (5 mL) and cooled to ⁇ 10° C. under N 2 atmosphere. To this cooled solution was added dropwise a mixture of 4-(piperidin-1-ylsulfonyl) aniline (300 mg, 1.248 mmol) and TEA (2.52 mmol) in DCM (10 mL). The mixture was stirred at ⁇ 10° C. for 5 minutes and allowed to warm up to room temperature for 1 hour. A solution tert-butyl 5-(aminomethyl)pyridin-2-ylcarbamate (293 mg, 1.311 mmol) and TEA (2.52 mmol) in DCM (5 mL) was then added.
  • the reaction mixture was stirred at room temperature for 16 hours.
  • the mixture was diluted with DCM (25 mL), washed with brine (2 ⁇ 15 mL), dried over MgSO 4 , filtered and concentrated under reduced pressure.
  • the crude was purified by Biotage using 5% MeOH/DCM to afford the desired product as a white amorphous powder (200 mg, 32.7% yield).
  • N-(5-chloro-2-methoxyphenyl)-4-cyanobenzenesulfonamide 0.387 mmol, 125 mg was dissolved in 2-propanol (8.0 mL) and 1.8 M aqueous potassium hydroxide (6.5 mL, 11.6 mmol).
  • the reaction was heated at 75° C. for 18 hours then cooled to ambient temperature and the 2-propanol removed on a rotary evaporator.
  • the aqueous phase was extracted with ethyl acetate (5 mL) then the pH was adjusted to pH 2-3 with 2N hydrochloric acid and the aqueous phase was extracted thrice with ethyl acetate (10 mL).
  • 6-chloronicotinonitrile 510 mg, 3.68 mmol
  • DMF dimethylamine
  • DIEA 3.0 mL, 17.18 mmol
  • the mixture was heated to 140° C. for 17 hours, and was then diluted with EtOAc and washed with brine (3 ⁇ ) and dried (MgSO 4 ). After filtration and concentration, the residue was purified by Biotage SP1 (100% MeOH/DCM/NH 3 ) to afford the title compound as a pale yellow solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
US13/820,496 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt Abandoned US20130273034A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/820,496 US20130273034A1 (en) 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US37981910P 2010-09-03 2010-09-03
US37981210P 2010-09-03 2010-09-03
US38604410P 2010-09-24 2010-09-24
US38603710P 2010-09-24 2010-09-24
US201161478995P 2011-04-26 2011-04-26
US201161480423P 2011-04-29 2011-04-29
US13/820,496 US20130273034A1 (en) 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt
PCT/US2011/050320 WO2012031196A1 (en) 2010-09-03 2011-09-02 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/050320 A-371-Of-International WO2012031196A1 (en) 2010-09-03 2011-09-02 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/008,378 Continuation US10329275B2 (en) 2010-09-03 2018-06-14 Compounds and compositions for the inhibition of NAMPT

Publications (1)

Publication Number Publication Date
US20130273034A1 true US20130273034A1 (en) 2013-10-17

Family

ID=44653564

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/820,496 Abandoned US20130273034A1 (en) 2010-09-03 2011-09-02 Novel compounds and compositions for the inhibition of nampt
US16/008,378 Active US10329275B2 (en) 2010-09-03 2018-06-14 Compounds and compositions for the inhibition of NAMPT
US16/419,333 Active US10647695B2 (en) 2010-09-03 2019-05-22 Compounds and compositions for the inhibition of NAMPT
US16/824,885 Active US11279687B2 (en) 2010-09-03 2020-03-20 Compounds and compositions for the inhibition of NAMPT

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/008,378 Active US10329275B2 (en) 2010-09-03 2018-06-14 Compounds and compositions for the inhibition of NAMPT
US16/419,333 Active US10647695B2 (en) 2010-09-03 2019-05-22 Compounds and compositions for the inhibition of NAMPT
US16/824,885 Active US11279687B2 (en) 2010-09-03 2020-03-20 Compounds and compositions for the inhibition of NAMPT

Country Status (13)

Country Link
US (4) US20130273034A1 (zh)
EP (1) EP2611777B1 (zh)
JP (2) JP6038792B2 (zh)
KR (1) KR20130114653A (zh)
CN (2) CN103270023B (zh)
AR (1) AR082887A1 (zh)
AU (1) AU2011295724B2 (zh)
BR (1) BR112013004858A8 (zh)
CA (1) CA2809391A1 (zh)
MX (1) MX342481B (zh)
RU (2) RU2016116533A (zh)
TW (1) TW201217359A (zh)
WO (1) WO2012031196A1 (zh)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
US10272072B2 (en) 2010-09-03 2019-04-30 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10323018B2 (en) 2015-01-20 2019-06-18 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
US10329275B2 (en) 2010-09-03 2019-06-25 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10392416B2 (en) 2015-10-02 2019-08-27 Metro International Biotech, Llc Crystal forms of beta-nicotinamide mononucleotide
US10548913B2 (en) 2015-08-05 2020-02-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US10696692B2 (en) 2012-03-02 2020-06-30 Forma Tm, Llc Amido-benzyl sulfone and sulfoxide derivates
US10730889B2 (en) 2012-03-02 2020-08-04 Forma Tm, Llc Amido spirocyclic amide and sulfonamide derivatives
WO2020191359A1 (en) * 2019-03-21 2020-09-24 Fred Hutchinson Cancer Research Center Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN114890990A (zh) * 2022-04-13 2022-08-12 中国人民解放军海军军医大学 一种化合物及在制备nampt蛋白自噬降解剂中的应用
US11479564B2 (en) 2011-05-09 2022-10-25 Valo Health, Inc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
CN115286617A (zh) * 2022-06-24 2022-11-04 中国人民解放军海军军医大学 一种靶向降解nampt的protac化合物及其应用
US11607419B2 (en) * 2017-06-06 2023-03-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibitors of RAC1 and uses thereof for inducing bronchodilatation
US11787830B2 (en) 2021-05-27 2023-10-17 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103313968A (zh) 2010-11-15 2013-09-18 Abbvie公司 Nampt和rock抑制剂
US9296723B2 (en) 2012-05-11 2016-03-29 Abbvie Inc. NAMPT inhibitors
PE20150224A1 (es) * 2012-05-11 2015-03-08 Abbvie Inc Inhibidores del nampt
WO2013170113A1 (en) * 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
CN104768931A (zh) * 2012-06-27 2015-07-08 向日葵研究有限责任公司(美国) 化合物及其治疗用途
WO2014062511A1 (en) * 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014074715A1 (en) * 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
JP2017521426A (ja) 2014-07-23 2017-08-03 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｎａｍｐｔ抑制物質としての４，５−ジヒドロイソオキサゾール誘導体
JP6755589B2 (ja) * 2015-04-30 2020-09-16 国立大学法人京都大学 Ａｍｐｋのリン酸化を亢進する化合物を有効成分とする組成物
SI3390355T1 (sl) * 2016-03-22 2023-07-31 Helsinn Healthcare S. A. Benzensulfonil-asimetrične sečnine in njihove medicinske uporabe
KR101869794B1 (ko) * 2016-07-20 2018-06-21 연세대학교 산학협력단 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물
EP3528850A4 (en) 2016-10-18 2020-06-24 Seattle Genetics, Inc. TARGETED ADMINISTRATION OF NICOTINAMIDE ADENIN DINUCLEOTIDE RECOVERY PATHWAY INHIBITORS
MA51189A (fr) 2017-04-27 2020-03-04 Seattle Genetics Inc Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
WO2019089478A1 (en) * 2017-10-30 2019-05-09 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
KR101937126B1 (ko) * 2018-06-15 2019-01-10 연세대학교 산학협력단 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물
WO2020010252A1 (en) 2018-07-05 2020-01-09 Daiichi Sankyo Company, Limited Fused ring compound having urea structure
CA3146157A1 (en) * 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
ES2828464A1 (es) * 2019-11-26 2021-05-26 Univ Murcia Inhibidores de la muerte celular por parthanatos para ser usados en el tratamiento de las enfermedades inflamatorias de la piel
FR3103702B1 (fr) * 2019-11-28 2022-02-11 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
US20230077499A1 (en) * 2019-12-20 2023-03-16 Merck Sharp & Dohme Llc Amido-substituted heterocyclic compounds and methods of use thereof for the treatment of herpes viruses
AU2021398569A1 (en) * 2020-12-11 2023-07-06 Scripps Research Institute, The Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
CN113278409B (zh) * 2021-06-22 2022-04-29 西南石油大学 一种高温酸化缓蚀剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994905A (en) * 1974-04-11 1976-11-30 Rohm And Haas Company 3-Pyridylmethyl aryl urea rodenticides

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931203A (en) 1973-03-19 1976-01-06 Rohm And Haas Company 3-Pyridylmethyl aryl urea rodenticides
AR205697A1 (es) * 1973-03-19 1976-05-31 Rohm & Haas Nuevos compuestos rodenticidas de 1 - (3 - piridilmetil) - 3 - (4 - substituido fenil o 4-nitronaftil) ureas composicion que los comprende y procedimiento para prepararlos
DE2334355A1 (de) 1973-07-06 1975-01-16 Hoechst Ag Diphenylharnstoffderivate und ihre herstellung
US4659724A (en) 1982-12-30 1987-04-21 Union Carbide Corporation Certain 1-[4-(5-cyano-2-pyridyloxy)phenyl-benzoyl ureas having pesticidal properties
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756236A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
GB9904275D0 (en) * 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
DE10053794A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Neue Verwendung für Amino- und Amidosulfonamide
US7238813B2 (en) 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
ES2200617B1 (es) * 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
DE10109204A1 (de) 2001-02-26 2002-09-19 4Sc Ag Verbindungen zur Behandlung von Protozoen-Erkrankungen
EP1395548A1 (en) 2001-02-26 2004-03-10 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
AU2002364260A1 (en) 2001-12-31 2003-07-30 Bayer Pharmaceuticals Corporation Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
JP2007512255A (ja) 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
JP2008536932A (ja) 2005-04-18 2008-09-11 サイード・アール・カーン チューブリン重合阻害剤：ボンゾイルフェニル尿素（ｂｐｕ）硫黄類似体の設計及び合成
BRPI0617513A2 (pt) 2005-10-20 2011-07-26 Sumitomo Chemical Co compostos de benzoilurÉia, processo para a produÇço e uso dos mesmos e mÉtodo para controlar pestes
CA2664364A1 (en) 2006-09-28 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
JP5688367B2 (ja) * 2008-08-29 2015-03-25 トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔ Ａ／Ｓ 新規なウレアおよびチオウレア誘導体
FR2943669B1 (fr) 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
WO2010142735A1 (en) * 2009-06-09 2010-12-16 Topotarget A/S Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase
CN102869261A (zh) * 2010-03-01 2013-01-09 瑞科西有限公司 化合物及其治疗应用
US9676721B2 (en) 2010-09-03 2017-06-13 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
CA2810038A1 (en) 2010-09-03 2012-03-08 Forma Tm, Llc Novel compounds and compositions for the inhibition of nampt
WO2012031196A1 (en) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
BR112013028281A2 (pt) 2011-05-04 2017-01-10 Forma Tm Llc compostos e composições para inibição de nampt
JP5872027B2 (ja) 2011-05-09 2016-03-01 フォーマ ティーエム， エルエルシー． ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
US10696692B2 (en) 2012-03-02 2020-06-30 Forma Tm, Llc Amido-benzyl sulfone and sulfoxide derivates
WO2013130935A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
SI2820008T1 (sl) 2012-03-02 2017-06-30 Genentech, Inc. Amido-spirociklični amidni in sulfonamidni derivati
ES2620612T3 (es) 2012-03-02 2017-06-29 Genentech, Inc. Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994905A (en) * 1974-04-11 1976-11-30 Rohm And Haas Company 3-Pyridylmethyl aryl urea rodenticides

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11279687B2 (en) 2010-09-03 2022-03-22 Valo Health, Inc. Compounds and compositions for the inhibition of NAMPT
US11547701B2 (en) 2010-09-03 2023-01-10 Valo Health, Inc. Compounds and compositions for the inhibition of NAMPT
US10772874B2 (en) 2010-09-03 2020-09-15 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10329275B2 (en) 2010-09-03 2019-06-25 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10456382B2 (en) 2010-09-03 2019-10-29 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10272072B2 (en) 2010-09-03 2019-04-30 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US10647695B2 (en) 2010-09-03 2020-05-12 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US11479564B2 (en) 2011-05-09 2022-10-25 Valo Health, Inc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
US10730889B2 (en) 2012-03-02 2020-08-04 Forma Tm, Llc Amido spirocyclic amide and sulfonamide derivatives
US11485745B2 (en) 2012-03-02 2022-11-01 Valo Health, Inc. Amido spirocyclic amide and sulfonamide derivatives
US10696692B2 (en) 2012-03-02 2020-06-30 Forma Tm, Llc Amido-benzyl sulfone and sulfoxide derivates
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
US10323018B2 (en) 2015-01-20 2019-06-18 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
US10548913B2 (en) 2015-08-05 2020-02-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US11878027B2 (en) 2015-08-05 2024-01-23 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US11464796B2 (en) 2015-08-05 2022-10-11 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US11059847B2 (en) 2015-10-02 2021-07-13 Metro International Biotech, Llc Crystal forms of β-nicotinamide mononucleotide
US10392416B2 (en) 2015-10-02 2019-08-27 Metro International Biotech, Llc Crystal forms of beta-nicotinamide mononucleotide
US11607419B2 (en) * 2017-06-06 2023-03-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibitors of RAC1 and uses thereof for inducing bronchodilatation
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20220125814A1 (en) * 2019-03-21 2022-04-28 Fred Hutchinson Cancer Research Center Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
WO2020191359A1 (en) * 2019-03-21 2020-09-24 Fred Hutchinson Cancer Research Center Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US11787830B2 (en) 2021-05-27 2023-10-17 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
US11952396B1 (en) 2021-05-27 2024-04-09 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
CN114890990A (zh) * 2022-04-13 2022-08-12 中国人民解放军海军军医大学 一种化合物及在制备nampt蛋白自噬降解剂中的应用
CN115286617A (zh) * 2022-06-24 2022-11-04 中国人民解放军海军军医大学 一种靶向降解nampt的protac化合物及其应用

Also Published As

Publication number Publication date
CN106986856A (zh) 2017-07-28
US10647695B2 (en) 2020-05-12
CN103270023B (zh) 2016-11-02
AU2011295724A1 (en) 2013-05-02
MX342481B (es) 2016-09-30
BR112013004858A8 (pt) 2018-01-02
WO2012031196A1 (en) 2012-03-08
EP2611777B1 (en) 2016-05-11
JP2017019825A (ja) 2017-01-26
US20190270721A1 (en) 2019-09-05
AR082887A1 (es) 2013-01-16
CA2809391A1 (en) 2012-03-08
AU2011295724A8 (en) 2013-06-20
CN103270023A (zh) 2013-08-28
TW201217359A (en) 2012-05-01
BR112013004858A2 (pt) 2016-06-07
JP2013536868A (ja) 2013-09-26
US20180291000A1 (en) 2018-10-11
US10329275B2 (en) 2019-06-25
RU2016116533A3 (zh) 2018-11-30
EP2611777A1 (en) 2013-07-10
KR20130114653A (ko) 2013-10-17
AU2011295724B2 (en) 2016-05-12
JP6038792B2 (ja) 2016-12-07
RU2013114844A (ru) 2014-10-10
MX2013002431A (es) 2013-06-03
US20200283403A1 (en) 2020-09-10
WO2012031196A9 (en) 2013-06-13
RU2016116533A (ru) 2018-11-30
RU2617424C2 (ru) 2017-04-25
US11279687B2 (en) 2022-03-22

Similar Documents

Publication Publication Date Title
US11279687B2 (en) Compounds and compositions for the inhibition of NAMPT
US11547701B2 (en) Compounds and compositions for the inhibition of NAMPT
US11479564B2 (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
US9676721B2 (en) Compounds and compositions for the inhibition of NAMPT
US9169209B2 (en) Compounds and compositions for the inhibition of NAMPT

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENENTECH, INC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YUEN, PO-WAI;REEL/FRAME:027210/0175

Effective date: 20110928

Owner name: FORMA THERAPEUTICS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAIR, KENNETH W.;BAUMEISTER, TIMM;BUCKMELTER, ALEXANDRE J.;AND OTHERS;SIGNING DATES FROM 20111020 TO 20111102;REEL/FRAME:027210/0124

AS Assignment

Owner name: GENENTECH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHARMARON, INC.;REEL/FRAME:031100/0961

Effective date: 20130514

Owner name: PHARMARON, INC., KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHARMARON BEIJING, CO., LTD;REEL/FRAME:031100/0950

Effective date: 20130514

Owner name: PHARMARON BEIJING, CO., LTD, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YUEN, PO-WAI;REEL/FRAME:031100/0882

Effective date: 20130513

Owner name: FORMA THERAPEUTICS INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAIR, KENNETH W.;BAUMEISTER, TIMM R.;BUCKMELTER, ALEXANRE J.;AND OTHERS;SIGNING DATES FROM 20130618 TO 20130621;REEL/FRAME:031101/0023

AS Assignment

Owner name: FORMA TM, LLC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORMA THERAPEUTICS, INC.;REEL/FRAME:033094/0875

Effective date: 20140522

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: FORMA THERAPEUTICS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORMA TM, LLC;REEL/FRAME:053387/0440

Effective date: 20200701

AS Assignment

Owner name: INTEGRAL EARLY DISCOVERY, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORMA THERAPEUTICS, INC.;REEL/FRAME:053402/0298

Effective date: 20200430

AS Assignment

Owner name: VALO EARLY DISCOVERY, INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:INTEGRAL EARLY DISCOVERY, INC.;REEL/FRAME:053787/0138

Effective date: 20200911